Characterization of an ETV6-NTRK3 rearrangement with unusual, but highly significant FISH signal pattern in a secretory carcinoma of the salivary gland: a case report.
Case report
ETV6-NTRK3 fusion
NTRK3 break apart FISH
Salivary gland
Secretory carcinoma
Journal
Diagnostic pathology
ISSN: 1746-1596
Titre abrégé: Diagn Pathol
Pays: England
ID NLM: 101251558
Informations de publication
Date de publication:
09 Aug 2021
09 Aug 2021
Historique:
received:
29
01
2021
accepted:
24
07
2021
entrez:
10
8
2021
pubmed:
11
8
2021
medline:
11
1
2022
Statut:
epublish
Résumé
Fusions of neurotrophic tropomyosin receptor kinase genes NTRK1, NTRK2 and NTRK3 with various partner genes occur in both common and rare tumours and are of paramount predictive value due to the availability of very effective pan-Trk inhibitors like Larotrectinib and Entrectinib. Detection of NTRK fusions is mainly performed by fluorescence in situ hybridization (FISH) and next generation sequencing (NGS). The case described here showed a very unusual, but highly significant FISH signal pattern with an NTRK3 break apart probe, indicative of a functional NTRK3 rearrangement. We describe here the case of a male patient who was originally diagnosed with an adenocarcinoma of the parotid gland without evidence of metastases. After the development of multiple lung metastases, an extensive immunohistochemical and molecular examination of archived tumour tissue including analysis of NTRK was performed. NTRK expression was detected by immunohistochemistry (IHC) and then comprehensively analysed further by FISH, quantitative reverse transcription PCR (RT-qPCR), and NGS. NTRK3 break apart FISH showed multiple and very faint single 3' signals in addition to fusion signals. Quantitative reverse transcription PCR and NGS confirmed an ETV6:exon5-NTRK3:exon15 fusion. Diagnosis was therefore revised to metastatic secretory carcinoma of the salivary gland, and the patient subsequently treated with Larotrectinib, resulting in persisting partial remission. Our findings underline the importance to be aware of non-canonical signal patterns during FISH analysis for detection of NTRK rearrangements. Very faint single 3' signals can indicate a functional NTRK rearrangement and therefore be of high predictive value.
Sections du résumé
BACKGROUND
BACKGROUND
Fusions of neurotrophic tropomyosin receptor kinase genes NTRK1, NTRK2 and NTRK3 with various partner genes occur in both common and rare tumours and are of paramount predictive value due to the availability of very effective pan-Trk inhibitors like Larotrectinib and Entrectinib. Detection of NTRK fusions is mainly performed by fluorescence in situ hybridization (FISH) and next generation sequencing (NGS). The case described here showed a very unusual, but highly significant FISH signal pattern with an NTRK3 break apart probe, indicative of a functional NTRK3 rearrangement.
CASE PRESENTATION
METHODS
We describe here the case of a male patient who was originally diagnosed with an adenocarcinoma of the parotid gland without evidence of metastases. After the development of multiple lung metastases, an extensive immunohistochemical and molecular examination of archived tumour tissue including analysis of NTRK was performed. NTRK expression was detected by immunohistochemistry (IHC) and then comprehensively analysed further by FISH, quantitative reverse transcription PCR (RT-qPCR), and NGS. NTRK3 break apart FISH showed multiple and very faint single 3' signals in addition to fusion signals. Quantitative reverse transcription PCR and NGS confirmed an ETV6:exon5-NTRK3:exon15 fusion. Diagnosis was therefore revised to metastatic secretory carcinoma of the salivary gland, and the patient subsequently treated with Larotrectinib, resulting in persisting partial remission.
CONCLUSIONS
CONCLUSIONS
Our findings underline the importance to be aware of non-canonical signal patterns during FISH analysis for detection of NTRK rearrangements. Very faint single 3' signals can indicate a functional NTRK rearrangement and therefore be of high predictive value.
Identifiants
pubmed: 34372873
doi: 10.1186/s13000-021-01133-z
pii: 10.1186/s13000-021-01133-z
pmc: PMC8353763
doi:
Substances chimiques
Biomarkers, Tumor
0
ETV6-NTRK3 fusion protein, human
0
Oncogene Proteins, Fusion
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
73Informations de copyright
© 2021. The Author(s).
Références
Head Neck Pathol. 2020 Jun;14(2):542-549
pubmed: 31273600
Mod Pathol. 2019 Jan;32(1):147-153
pubmed: 30171197
J Thorac Oncol. 2012 Sep;7(9):e14-6
pubmed: 22895149
Ann Oncol. 2019 Nov 1;30(Suppl_8):viii23-viii30
pubmed: 31738426
Ther Clin Risk Manag. 2018 Jul 20;14:1247-1252
pubmed: 30050303
Am J Surg Pathol. 2010 May;34(5):599-608
pubmed: 20410810
Lung Cancer. 2020 May;143:80-85
pubmed: 32272316
Ann Oncol. 2019 Sep 1;30(9):1417-1427
pubmed: 31268127
Am J Surg Pathol. 2016 Jan;40(1):3-13
pubmed: 26492182
Mod Pathol. 2020 Jan;33(1):38-46
pubmed: 31375766
Nat Rev Clin Oncol. 2018 Dec;15(12):731-747
pubmed: 30333516
Expert Rev Clin Pharmacol. 2019 Oct;12(10):931-939
pubmed: 31469968
J Clin Pathol. 2019 Jul;72(7):460-467
pubmed: 31072837
Cancer Res. 2019 Jul 1;79(13):3163-3168
pubmed: 31196931